{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:11:30Z","timestamp":1766509890410,"version":"3.48.0"},"reference-count":15,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,12]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Venetoclax\u2010based (ven) combinations have become a standard of care for acute myeloid leukemia (AML) patients ineligible for intensive chemotherapy. However, the associated risk of infectious adverse events (IAEs) remains a significant clinical concern.<\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n This study aimed to evaluate the incidence, characteristics, and risk factors for IAEs in newly diagnosed AML patients treated with venetoclax combinations in a real\u2010world setting.<\/jats:p>\n <\/jats:sec>\n \n Methods and Results<\/jats:title>\n \n We conducted a retrospective cohort study of AML patients treated with ven in combination with hypomethylating agents or low\u2010dose cytarabine (LDAC), with analyses performed on a treatment cycle basis. Clinical and laboratory data, including IAE characteristics, duration of neutropenia, and concomitant medications, were collected, and grade \u2265\u20092 IAEs were included according to CTCAE v5.0 criteria. The cohort included 143 treatment cycles of 43 patients, with a median neutropenia duration of 13\u2009days (5\u201335). A total of 34 (23.8%) grade \u2265\u20092 IAEs occurred, with an incidence of 1 per 121 patient\u2010days. Multivariate analysis identified prolonged neutropenia (days, OR\u2009=\u20091.037,\n p<\/jats:italic>\n \u2009=\u20090.005) and interacting concomitant medications (OR\u2009=\u20099.99,\n p<\/jats:italic>\n \u2009<\u20090.001) as independent risk factors for IAEs. The rate of invasive fungal infections was as low as 3.5%, and the use of antifungal or antibacterial prophylaxis was not associated with a reduction in the rate of IAEs.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n IAEs remain a substantial risk in venetoclax\u2010treated AML patients, particularly during prolonged neutropenia and with concomitant drug interactions. Optimizing venetoclax regimens and careful management of interacting medications may mitigate these risks.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cnr2.70432","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:08:59Z","timestamp":1766473739000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors for Infectious Adverse Events in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Venetoclax Combinations: A Retrospective Single\u2010Centre Real\u2010World Experience"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1226-5797","authenticated-orcid":false,"given":"Olgu Erkin","family":"\u00c7\u0131nar","sequence":"first","affiliation":[{"name":"Department of Hematology Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2499-0101","authenticated-orcid":false,"given":"Azade","family":"Kanat","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-6495","authenticated-orcid":false,"given":"Kerim","family":"Erer","sequence":"additional","affiliation":[{"name":"Department of Hematology Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9476-4844","authenticated-orcid":false,"given":"Rasim","family":"\u015eahin","sequence":"additional","affiliation":[{"name":"Department of Hematology Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2712-9694","authenticated-orcid":false,"given":"Esma Ery\u0131lmaz","family":"Eren","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-5761","authenticated-orcid":false,"given":"Esra","family":"Y\u0131ld\u0131zhan","sequence":"additional","affiliation":[{"name":"Department of Hematology Kayseri City Training and Education Hospital Kayseri Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26822"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011964"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05102-y"},{"key":"e_1_2_12_5_1","unstructured":"C.T.E. Program \u201cCommon Terminology Criteria for Adverse Events (CTCAE) \u201d 2017 accessed November 23 2024 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020004856"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-171105"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-178297"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149523"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187383"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27515"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18051"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-187206"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33508"},{"key":"e_1_2_12_16_1","unstructured":"AbbVie Inc \u201cVenclexta (Venetoclax Tablets) Drug Interaction Brochure \u201d 2022 accessed December 23 2024 https:\/\/www.venclextahcp.com\/content\/dam\/gene\/venclextahcp\/combo\/pdfs\/venclexta\u2010ddi\u2010brochure.pdf."}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:45:24Z","timestamp":1766508324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cnr2.70432"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70432","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70432"}}